Is EXOVO LTD a Scam?

When we at FXCanary evaluate a broker, we start from the regulatory record, not from marketing materials. For EXOVO LTD, the known facts are sparse but significant: the firm is registered in Cyprus and holds a single CySEC licence, number 417/22, with the status 'Authorised'. That licence is a CIF (Cyprus Investment Firm) authorisation, which places the firm squarely inside the European Union's MiFID II framework. In our assessment, a live CySEC licence is a meaningful positive signal, because it brings with it a defined set of conduct rules, capital requirements and client-protection obligations.

However, a licence alone does not tell the whole story. Our FXCanary Scam Risk Score for EXOVO LTD stands at 34 out of 100, which we classify as 'Guarded'. The score is not driven by any evidence of fraud or misconduct — there are no clone sites on file and no regulatory warnings against the firm.

Rather, the score reflects a notable absence: we could not verify an active website or any social-media presence for the broker. For a regulated firm, that silence is unusual and warrants caution. A trader cannot fully assess a broker they cannot see, and we treat that lack of verifiable public footprint as a risk factor in its own right.

EXOVO LTD's authorisation is a CySEC CIF licence, number 417/22, and the status is listed as 'Authorised'. We cross-checked this against the public register and the firm's own risk-disclosure page, which confirms the licence number. Being a CySEC-regulated CIF means the firm is subject to the Investment Services and Activities and Regulated Markets Law of 2017, as referenced in its own disclosures. That law transposes MiFID II into Cypriot law, and it imposes real obligations: the firm must maintain adequate capital, report to the regulator, and treat client money according to strict rules.

One of the most important protections for a retail client under CySEC is client-money segregation. In simple terms, client funds must be held in accounts separate from the firm's own operating funds, so that if the broker becomes insolvent, client money should not be swept into the bankruptcy estate. This is a genuine safeguard, but it is not absolute. Segregation protects against the broker's failure, not against losses from trading, and it does not guarantee that every euro will be recovered in every scenario. We always remind traders that segregation is a structural protection, not a promise of zero risk.

As a CySEC-regulated firm, EXOVO LTD is a member of the Cyprus Investor Compensation Fund (ICF). The ICF is designed to compensate eligible clients if a member firm fails and is unable to return client money or assets. The standard coverage is up to €20,000 per eligible client. This is a meaningful backstop for retail traders, though it has limits: it does not cover investment losses, and the process of claiming can take time. In our view, the ICF is a credible safety net, but it should never be the primary reason a trader chooses a broker.

Another key protection under the European framework is negative-balance protection for retail clients. This means that, under normal circumstances, a retail client cannot lose more than the balance in their trading account. If the market gaps and losses exceed the account balance, the broker is required to absorb the excess. This is a significant advantage over many offshore brokers, which may not offer such protection. For a retail trader, this feature alone can be the difference between a controlled loss and a catastrophic one.

Our web search returned a mix of results, and we approached them with caution. Several results refer to RoboMarkets and ORBEX, which are entirely different brokers with their own CySEC licences. We discarded those as irrelevant to EXOVO LTD.

The relevant results are the firm's own risk-disclosure page and its homepage, both on exovo.com.cy, plus a profile on an industry database and a company-registry entry. The company-registry entry shows that EXOVO LTD was registered in Cyprus on 17 May 1993, with company number ΗΕ 55341, and is listed as an active private limited company. The industry profile repeats the licence number 417/22 and describes the firm as active for retail and professional clients.

However, we found no independent user reviews of EXOVO LTD as a forex broker. The firm's own website describes it as a capital-markets company offering access to markets, hedging and bespoke investment solutions, and it states that it employs one person. That last detail is striking.

A one-person investment firm, even with a CySEC licence, raises questions about operational capacity and the depth of client support. We are not implying any wrongdoing, but we are obliged to point out that the public footprint is thin, and the firm's own marketing language is general rather than specific about trading conditions, spreads or platforms. In FXCanary's assessment, the absence of independent reviews and detailed disclosures is itself a finding.

Our records show zero clone or impersonator sites for EXOVO LTD. That is a positive sign, because clone scams are a common threat in the forex industry, where fraudsters set up lookalike websites using a regulated firm's name and licence number to lure victims. The fact that we have found no such clones suggests that the firm's name is not currently being abused in that way. However, this can change quickly, and we advise traders to verify the official domain — exovo.com.cy — before engaging with any entity claiming to be EXOVO.

We also note that the firm's own website is live and carries the correct licence number, which is a good sign of authenticity. Still, the broader risk is that a trader searching for 'EXOVO' might land on a different, unaffiliated site with a similar name. Our search results included RoboMarkets and ORBEX, both of which are legitimate but unrelated. This is a reminder that domain names and brand names can be confusingly similar, and traders should always check the exact URL and cross-reference the licence number on the CySEC register before depositing funds.

If you are considering EXOVO LTD, the first step is to verify the licence directly on the CySEC website. Search for 'EXOVO LTD' and confirm that the licence number 417/22 matches exactly, and that the status is 'Authorised'. Do not rely on a screenshot or a link from an email — go to the regulator's site yourself.

Next, check the firm's official domain, exovo.com.cy, and look for a risk-disclosure document and a client-agreement page. A regulated firm should publish these. If you cannot find them, treat that as a red flag.

Before depositing, ask the broker directly for its legal entity name, its licence number, and its registered address. Cross-check those details against the public register. Be wary of any request to send funds to a bank account in a different name or jurisdiction. And remember that even with a CySEC licence, you are not protected against trading losses — only against certain types of broker failure. Trade only with money you can afford to lose, and start with a small deposit to test the firm's execution and customer service before committing more.

In FXCanary's assessment, EXOVO LTD is a regulated but low-profile broker. The CySEC licence is real and current, and the firm has been registered in Cyprus since 1993, which gives it a long corporate history. The absence of clone sites is reassuring. But the lack of a verifiable website footprint, the absence of independent reviews, and the firm's own description of a one-person operation all point to a broker that is, at best, early in its public-facing journey or, at worst, not fully transparent.

We would classify EXOVO LTD as 'Guarded' rather than 'Safe' or 'Risky'. That means a trader can proceed, but only with eyes wide open. Verify everything independently, start small, and do not assume that the CySEC badge alone makes this a top-tier choice. For most retail traders, a broker with a more established public presence and a longer track record of client reviews may be a more comfortable option. We will continue to monitor EXOVO LTD and update this assessment as more information becomes available.